These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 8602023)

  • 41. Pertussis infection and vaccination induces Th1 cells.
    Brady MT; Mahon BP; Mills KH
    Immunol Today; 1998 Nov; 19(11):534. PubMed ID: 9818551
    [No Abstract]   [Full Text] [Related]  

  • 42. [Pathogenetic significance of Bordetella pertussis toxin].
    Finger H
    Immun Infekt; 1985 Apr; 13(2):47-9. PubMed ID: 2860059
    [No Abstract]   [Full Text] [Related]  

  • 43. Serospecific protection of mice against intranasal infection with Bordetella pertussis.
    Robinson A; Gorringe AR; Funnell SG; Fernandez M
    Vaccine; 1989 Aug; 7(4):321-4. PubMed ID: 2573215
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acellular pertussis vaccines for infants.
    Edwards KM; Decker MD
    N Engl J Med; 1996 Feb; 334(6):391-2. PubMed ID: 8538712
    [No Abstract]   [Full Text] [Related]  

  • 45. The control of pertussis--2007 and beyond.
    Halperin SA
    N Engl J Med; 2007 Jan; 356(2):110-3. PubMed ID: 17215528
    [No Abstract]   [Full Text] [Related]  

  • 46. [Immune response to various antigenic preparations of Bordetella pertussis in whooping cough patients and convalescents studied by immunoenzyme analysis].
    Tsvetkova NV; Borisenko IuV; Selezneva TS; Baeva EA
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Oct; (10):53-6. PubMed ID: 2879403
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity of acellular pertussis vaccines using two vaccines for primary immunization.
    von König CH; Herden P; Palitzsch D; Schneeweiss B; Bier N
    Pediatr Infect Dis J; 2000 Aug; 19(8):757-9. PubMed ID: 10959748
    [No Abstract]   [Full Text] [Related]  

  • 48. Evolution of whooping cough bacterium may reduce vaccine effectiveness.
    Riedmann EM
    Hum Vaccin Immunother; 2014; 10(6):1430. PubMed ID: 25396233
    [No Abstract]   [Full Text] [Related]  

  • 49. Immunoglobulin E response to pertussis toxin in whooping cough and after immunization with a whole-cell and an acellular pertussis vaccine.
    Hedenskog S; Björkstén B; Blennow M; Granström G; Granström M
    Int Arch Allergy Appl Immunol; 1989; 89(2-3):156-61. PubMed ID: 2759713
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Engineering bacterial toxin for the development of new vaccine against pertussis.
    Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R
    Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pertussis (whooping cough) toxin and Bordetella pertussis whole-cell antibody levels in a healthy New Zealand population.
    Lau RC
    N Z Med J; 1989 Oct; 102(878):560-2. PubMed ID: 2554227
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of the protective effects of the pertussis acellular vaccine with the component vaccine, which have different amounts of fimbriae, against the experimental aerosol infection of mice with Bordetella pertussis.
    Morokuma K; Ginnaga A; Nishihara T; Tsunoda S; Furukawa M; Aihara K; Sakoh M
    Dev Biol Stand; 1991; 73():223-32. PubMed ID: 1685713
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Roads to the development of improved pertussis vaccines paved by immunology.
    Brummelman J; Wilk MM; Han WG; van Els CA; Mills KH
    Pathog Dis; 2015 Nov; 73(8):ftv067. PubMed ID: 26347400
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunity to Bordetella pertussis.
    Mills KH
    Microbes Infect; 2001 Jul; 3(8):655-77. PubMed ID: 11445452
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunity to pertussis. Not all virulence factors are protective antigens.
    Robbins JB; Schneerson R; Bryla DA; Trollfors B; Taranger J; Lagergård T
    Adv Exp Med Biol; 1998; 452():207-18. PubMed ID: 9889975
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Investigation of role of nitric oxide in protection from Bordetella pertussis respiratory challenge.
    Canthaboo C; Xing D; Wei XQ; Corbel MJ
    Infect Immun; 2002 Feb; 70(2):679-84. PubMed ID: 11796599
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bordetella filamentous hemagglutinin and fimbriae: critical adhesins with unrealized vaccine potential.
    Scheller EV; Cotter PA
    Pathog Dis; 2015 Nov; 73(8):ftv079. PubMed ID: 26416077
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study.
    Le T; Cherry JD; Chang SJ; Knoll MD; Lee ML; Barenkamp S; Bernstein D; Edelman R; Edwards KM; Greenberg D; Keitel W; Treanor J; Ward JI;
    J Infect Dis; 2004 Aug; 190(3):535-44. PubMed ID: 15243929
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long term serologic follow-up after pertussis immunization.
    Blennow M; Granström M
    Pediatr Infect Dis J; 1990 Jan; 9(1):21-6. PubMed ID: 2300411
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of peptide loops of the Bordetella pertussis protein P.69 pertactin in antibody recognition.
    Hijnen M; de Voer R; Mooi FR; Schepp R; Moret EE; van Gageldonk P; Smits G; Berbers GA
    Vaccine; 2007 Aug; 25(31):5902-14. PubMed ID: 17597264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.